C4 Therapeutics (CCCC)
(Real Time Quote from BATS)
$6.50 USD
+0.06 (0.93%)
Updated Jul 26, 2024 03:44 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CCCC 6.50 +0.06(0.93%)
Will CCCC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCCC
Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
Other News for CCCC
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
C4 Therapeutics: Losing Steam And Presenting An Opportunity
C4 Therapeutics Appoints Mr. Cooper to Board
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors